VERV Troy Lister sells $9K worth of shares
Apr 04, 2025, 4:36 AM
0.00%
What does VERV do
Verve Therapeutics, based in Boston, focuses on gene editing for cardiovascular diseases, employing 255 staff and going public on June 17, 2021. Its lead programs, VERVE-101, VERVE-102, and VERVE-201, target LDL-C-related genes.
Troy Lister sold 2,189 shares of VERV on 2 April at $4.15 per share, worth a total of $9K. They now own 6,952 VERV shares, or a 24% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.